Our results confirmed that BAL is a rare malignancy with a very poor prognosis. Patients with ALL-directed chemotherapy achieved a better CR rate compared to those with AML-directed chemotherapy. Patients should receive HSCT after initial CR whenever it is possible.
Keyphrases
- poor prognosis
- end stage renal disease
- long non coding rna
- case report
- ejection fraction
- chronic kidney disease
- newly diagnosed
- locally advanced
- acute myeloid leukemia
- prognostic factors
- peritoneal dialysis
- squamous cell carcinoma
- radiation therapy
- allogeneic hematopoietic stem cell transplantation
- rectal cancer
- hematopoietic stem cell